Lontoon puolella on viime aikoina vaikuttanut erittäin kova Bex-fani (epäilen vähintäin tämän palstan jäseneksi)
Tässä pari viimeisintä postausta:
Https://www.tandfonline.com/doi/full/10.1080/10428194.2022.2034155
“…This was deemed as ‘clinical activity’ in HMA- refractory MDS, yet 89% of patients at 5.6 months follow-up had died. Just incase anyone was doubting that we actually have something meaningful here…
And what if the blockade of clever-1 and clearance of secreted clever-1 allows the likes of Keytruda to be effective in both liquid and solid tumours. Well then Bexmarilimab becomes Uber-Blockbuster…!!!”
Https://www.targetedonc.com/view/luspatercept-s-impact-on-low-risk-mds-a-shift-in-treatment-strategy
“Reblozyl, BMS’s drug, extending life in low risk MDS.
“Looking ahead, the next step will be to explore rational combination therapies to further increase response rates and improve patient outcomes.”
Can think of one that could be a good combination therapy and another reason for BMS to pursue Bexmarilimab, doubling the total addressable market in MDS…”